Arquivos do dia: Dezembro 15, 2021
M-A | Porcentagem global de infecções assintomáticas por SARS-CoV-2 é em torno de 40%.
15 Dez, 2021 | 12:48hComentário: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay
[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.
15 Dez, 2021 | 12:47hComunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death
Comentários:
Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT
Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press
Conteúdos relacionados:
8 lingering questions about the new Covid pills from Merck and Pfizer.
Comentário no Twitter (fio – clique para saber mais)
@pfizer releases more nirmatrelvir (#Paxlovid) data on #COVID19 final outcomes. Data are consistent, slightly better thant interim analysis. #IDTwitter
▪️ 88% overall hospitalization <=5days
▪️ No deaths in High Risk Trial (EPIC-HR)
▪️ Stopping drug 2.1%https://t.co/1D2LKan7tM— David Boulware, MD MPH (@boulware_dr) December 14, 2021
Riscos de miocardite, pericardite e arritmias cardíacas associadas à vacinação contra COVID-19 vs. infecção por SARS-CoV-2.
15 Dez, 2021 | 12:45hComunicado de imprensa: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford
Comentários no Twitter
Hugely important work from @JuliaHCox and colleagues:
In people <40, Pfizer carries a much lower risk of myocarditis than either Moderna **or SARS-CoV-2 infection** (annotations added)https://t.co/wqRts3ALqy pic.twitter.com/fnn1T39h1b
— David Juurlink (@DavidJuurlink) December 14, 2021
A case series published in @NatureMedicine shows an increased risk of myocarditis after receiving the Astra-Zeneca-Oxford, Pfizer-BioNTech and the Moderna COVID-19 vaccines, but SARS-CoV-2 infection carried a greater risk of myocarditis. https://t.co/6y7pZlJN70 pic.twitter.com/cBlKz9sUkg
— Nature Portfolio (@NaturePortfolio) December 14, 2021
Just published @NatureMedicine
The most comprehensive assessment of the rare events of myocarditis, pericarditis, arrhythmias after COVID and AZ, mRNA vaccineshttps://t.co/0bEdMJSLXg pic.twitter.com/eC5JOx0CmG— Eric Topol (@EricTopol) December 14, 2021
Estudo sugere que os comprovantes de vacinação contra COVID-19 podem reforçar a imunização em países com cobertura vacinal abaixo da média.
15 Dez, 2021 | 12:43hComunicado de imprensa: COVID-19 certificates may boost vaccine uptake in countries with below average coverage – University of Oxford
Estudo original: The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries – The Lancet Public Health
Comentário no Twitter
In our paper @TheLancetPH, @melindacmills and I found that mandatory vaccine passports are effective in increasing vaccine uptake! Already between announcement and introduction, France, Israel and Italy had strong uptick in vaccinations, esp young people: https://t.co/K0xnPdc4o1 https://t.co/WGvhpZjhyo pic.twitter.com/KGCNFmFgVD
— Tobias Rüttenauer (@ruettenauer) December 14, 2021
De disseminação rápida, a variante Ômicron está atualmente em 77 países e a OMS adverte contra presumir que seus efeitos sejam leves.
15 Dez, 2021 | 12:42h[Ainda não publicado] Dados iniciais da África do Sul mostram que, diante de infecção pela variante Ômicron, a proteção vacinal pode cair a 30%, mas ainda impede a doença grave.
15 Dez, 2021 | 12:40hVaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR
Ver também: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP
COVID-19 em 2022: o controle da pandemia está ao nosso alcance.
15 Dez, 2021 | 12:38hCOVID-19 in 2022: controlling the pandemic is within our grasp – Nature Medicine
Comentários no Twitter
What will the COVID-19 pandemic look like in 2022?
Who better to ask than @mvankerkhove, one of the busiest people in the world right now, who took the time to write this thoughtful World View for @NatureMedicine.https://t.co/jgodgPIDrK
— Ben Johnson 🦠📝 (@drbenjohnson) December 14, 2021
Vaccine inequity, inconsistent public health measures and new variants such as Omicron are prolonging the COVID-19 pandemic, but controlling the virus remains possible.
Worldview from @mvankerkhove @WHOhttps://t.co/vLmASqI8i7
— Nature Medicine (@NatureMedicine) December 14, 2021
Consenso de especialistas e diretriz prática | Perspectiva global sobre a melhora no cuidado do paciente com infecção de trato urinário não complicada.
15 Dez, 2021 | 12:36hPosicionamento científico | Diagnóstico, tratamento e prevenção da ingestão de baterias na infância.
15 Dez, 2021 | 12:33hResumo visual: Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood
Comentário no Twitter (fio – clique para saber mais)
Button battery ingestion in children⚠️: Important🆕 guidelines for diagnosis and management from @ESPGHANSociety #GITwitter https://t.co/TQ1rfjQOpShttps://t.co/fxzzCEl2F2
— ESGE (@ESGE_news) December 14, 2021
M-A | Farmacoterapia para adultos com sobrepeso e obesidade – “Fentermina–topiramato e agonistas de receptores de GLP-1 provaram ser os melhores medicamentos na redução de peso.”
15 Dez, 2021 | 12:31hPharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
Pharmacotherapy for adults with overweight and #obesity – NEW systematic review and network meta-analysis of RCTs summarises the latest evidence for the benefits and harms of weight-lowering drugs. https://t.co/92fK1cKcww pic.twitter.com/INUe2plSQB
— The Lancet (@TheLancet) December 9, 2021